Method for evaluating curative effect of Jinbifidus and compound glutamine combined enteric capsule
Through controlled studies and multiple evaluation methods, Jindianqi combined with compound glutamine enteric capsules significantly reduced the incidence of radioprotic inflammation, solved the problem of effectiveness evaluation and remission of radioprotic inflammation treatment, and improved the quality of life and intestines of patients Tao health.
Patent Information
- Application Number
- CN202411268385.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-11
- Publication Date
- 2024-12-06
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art is difficult to effectively treat radioprotic inflammation, especially in the remission of symptoms in patients after radiotherapy for rectal cancer, and there is a lack of effective evaluation and treatment methods.
Through randomized controlled studies, patients with locally advanced rectal cancer were selected, and Jinshuangqi combined with compound glutamine enteric capsules were given for treatment. Various grading standards, imaging evaluation and second-generation sequencing were used to observe the incidence of radioprotic inflammation in the patients. Remission rate and intestinal flora changes, and the efficacy was evaluated.
This method can accurately evaluate the efficacy of Jindianqi combined with compound glutamine enteric capsules in the treatment of radioprotic inflammation, significantly reducing the incidence of acute radioprotic inflammation of grade ≥2, and improving the quality of life and intestinal health of patients.
Smart Images

Figure CN119074965A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of treating radiation proctitis with Jinshuangqi combined with compound glutamine enteric-coated capsules, and specifically to a method for evaluating the efficacy of Jinshuangqi combined with compound glutamine enteric-coated capsules. Background Art
[0002] Rectal cancer is a major disease that currently threatens human life and health. It has been on the rise in the past few decades. The treatment of rectal cancer is usually a comprehensive treatment based on surgery combined with radiotherapy and chemotherapy, and most patients require radiotherapy. Although radiotherapy significantly prolongs the survival of patients, its physical damage to normal tissues can lead to damage to pelvic and abdominal organs, among which rectal injury is the most common and stubborn. Therefore, finding new means of treating radiation proctitis is of great clinical significance.
[0003] Animal studies have shown that probiotics can compete with the intestinal wall to inhibit pathogenic bacteria and have a preventive effect on radiation enteritis. Golden Bifidobacterium is composed of long bifidobacterium, bulgaricus and thermophilic streptococcus, which can promote the reproduction of bifidobacteria, secrete galactosidase, enhance intestinal vitality, accelerate nutrient absorption, and balance intestinal flora. Therefore, it has a reliable theoretical basis for the treatment of acute radiation proctitis and the comparison of changes in intestinal flora before and after treatment.
[0004] Compound Glutamine Enteric-coated Capsules are composed of the traditional Chinese medicine formula Sijunzi Decoction (ginseng, Atractylodes macrocephala, Poria cocos, and licorice) and glutamine. Sijunzi Decoction can invigorate Qi and strengthen the spleen, and is used for symptoms such as abdominal distension, intestinal rumbling and diarrhea caused by spleen and stomach Qi deficiency, and regulates the function of the digestive system as a whole. Glutamine is a non-essential amino acid and a special nutrient for gastrointestinal mucosal cells. It is an essential nitrogen donor for the synthesis of purine and pyrimidine, which are necessary substrates for the synthesis of nucleic acids. It is a nitrogen donor for the synthesis of nucleic acids and proteins, and plays an important role in the regeneration of intestinal mucosa and the maintenance of intestinal barrier function.
[0005] The present application has found through preliminary clinical practice that intestinal probiotics combined with compound glutamine can significantly improve the symptoms of radiation proctitis after radiotherapy for rectal cancer. Therefore, on this basis, a multicenter, prospective, randomized controlled study was conducted to explore the incidence of acute radiation proctitis of grade 2 or above in patients with locally advanced rectal cancer undergoing radiotherapy after the combination of the two. The clinical symptoms, colonoscopy, imaging, and changes in the species and abundance of intestinal flora of patients before and after treatment were observed through a variety of grading standards, second-generation sequencing, and other methods. The relationship between intestinal flora and the efficacy of radiotherapy was analyzed, thereby further exploring the related pathways and mechanisms that affect radiation enteritis. Therefore, a method for evaluating the efficacy of Jinshuangqi combined with compound glutamine enteric-coated capsules is proposed. Summary of the invention
[0006] The purpose of the present invention is to provide a method for evaluating the therapeutic effect of Jinshuangqi combined with compound glutamine enteric-coated capsules to solve the problems in the above-mentioned background technology.
[0007] To achieve the above object, the present invention provides the following technical solution: a method for evaluating the efficacy of Jinshuangqi combined with compound glutamine enteric-coated capsules, comprising the following steps:
[0008] Step 1, select patient samples:
[0009] The sample criteria were set and cases were selected. The subjects were patients with locally advanced rectal cancer who were planned to undergo neoadjuvant synchronous chemoradiotherapy before surgery.
[0010] Step 2, grouping:
[0011] The selected patients were randomly divided into two groups, which were set as the combined treatment group and the blank control group;
[0012] Step 3, medication:
[0013] Combined treatment group: from the first day of radiotherapy, 4 tablets of Jinshuangqi tablets were given 3 times a day, and compound glutamine enteric-coated capsules were taken orally 3 capsules each time, 3 times a day, half an hour after meals, until 1 month after the end of radiotherapy;
[0014] Blank control group: no drug intervention;
[0015] Step 4, Evaluation:
[0016] Compared with the efficacy evaluation criteria, the tests were performed according to the test items to evaluate the incidence and remission rate of radiation proctitis, colonoscopy evaluation, imaging evaluation, changes in intestinal flora, inflammatory factor detection, and quality of life;
[0017] Step 5, statistical analysis:
[0018] The Kaplan-Meier method was used to calculate the incidence and remission rate of radiation proctitis in the subjects, and the Log-rank test was used to compare the differences between the two groups.
[0019] Preferably, the standard of the sample in step 1 is:
[0020] (1) Patients aged 18-75 years with locally advanced rectal adenocarcinoma confirmed by histopathology and clinical stage cT3-4N0-2M0 diagnosed by pelvic MRI who are scheduled to undergo neoadjuvant concurrent chemoradiotherapy before surgery;
[0021] (2) No concurrent other malignant tumors;
[0022] (3) Those without serious heart, liver, kidney or other diseases;
[0023] (4) Voluntarily sign the informed consent form;
[0024] (5) PS score: 0-1.
[0025] Preferably, the grouping ratio of the combined treatment group and the blank control group is 1:1.
[0026] Preferably, in step 3, patients with radiation proctitis ≥ grade 2 in the control group are crossed over to the combined treatment group.
[0027] Preferably, the efficacy evaluation criteria are as follows:
[0028] (1) Effectiveness evaluation:
[0029] During neoadjuvant chemoradiotherapy, follow-up was performed weekly to evaluate the occurrence and grade of radiation proctitis in patients according to the RTOG acute radiation injury grading standard and record them;
[0030] Colonoscopy was used to observe the intestinal mucosa within 1 week before neoadjuvant therapy, during radiotherapy, at the end of radiotherapy, and 1 month after radiotherapy, using the Vienna colonoscopy scoring criteria;
[0031] Within 1 month before neoadjuvant therapy and 1 month after the end of radiotherapy, high-resolution + DWI pelvic enhanced MRI was used to evaluate tumor changes according to RECIST1.1;
[0032] In addition, the EORTC quality of life survey core questionnaire QLQ-C30 was used to assess the patients’ quality of life every week;
[0033] (2) Safety evaluation:
[0034] During neoadjuvant therapy, subjects need to have outpatient follow-up once a week for symptom questioning and physical examination, and weekly blood routine and biochemical tests to determine whether the patient can continue with neoadjuvant chemoradiotherapy to ensure the safety of treatment.
[0035] Preferably, the detection items include:
[0036] (1) Blood test:
[0037] During neoadjuvant therapy, routine blood tests and biochemical 1+4 tests are required once a week to determine whether the patient can continue neoadjuvant chemoradiotherapy to ensure the safety of treatment. At the same time, blood samples are collected within 1 week before neoadjuvant therapy, during radiotherapy, at the end of radiotherapy, and 1 month after the end of radiotherapy for subsequent detection of inflammatory factors.
[0038] (2) Fiberoptic colonoscopy evaluation:
[0039] Colonoscopy was used to observe the intestinal mucosa within 1 week before neoadjuvant therapy, during radiotherapy, at the end of radiotherapy, and 1 month after radiotherapy, using the Vienna colonoscopy scoring system.
[0040] (3) Radiological evaluation:
[0041] High-resolution + DWI pelvic enhanced MRI was used to evaluate tumor changes within 1 month before neoadjuvant therapy and 1 month after radiotherapy.
[0042] (4) Stool collection:
[0043] Feces of the subjects were collected one week before treatment, during radiotherapy, and one month after treatment. Next-generation sequencing was used to detect changes in the intestinal flora of the patients at different time points, and to detect changes in the species and abundance of fecal flora.
[0044] (5) Clinical symptoms and quality of life assessment: During neoadjuvant chemoradiotherapy, patients were followed up weekly to assess the frequency of bowel movements, duration of diarrhea, abdominal pain, abdominal distension, degree of tenesmus, presence of mucus and blood in the stool, and duration of remission using the RTOG acute radiation injury grading standard. At the same time, the EORTC quality of life survey core questionnaire QLQ-C30 was used to assess the quality of life of patients weekly.
[0045] The present invention has at least the following beneficial effects:
[0046] The present invention provides a method for evaluating the efficacy of Jinshuangqi combined with compound glutamine enteric-coated capsules. By selecting patient samples, grouping them, comparing the administration, and then performing efficacy evaluation and statistical analysis, the incidence rate, remission rate and other detection indicators of radiation proctitis can be observed and obtained. The evaluation result has a high accuracy rate and can better assist the treatment of radiation proctitis. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] Figure 1 It is a schematic diagram of the process of the present invention. DETAILED DESCRIPTION
[0048] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0049] Example
[0050] The method for evaluating the efficacy of Jinshuangqi combined with compound glutamine enteric-coated capsules provided in the present application comprises the following steps:
[0051] Step 1, select patient samples:
[0052] The sample criteria were set and cases were selected. The subjects were patients with locally advanced rectal cancer who were planned to undergo neoadjuvant synchronous chemoradiotherapy before surgery.
[0053] Step 2, grouping:
[0054] The selected patients were randomly divided into two groups, namely the combined treatment group (Jinshuangqi combined with compound glutamine enteric-coated capsules treatment group) and the blank control group (i.e. no drug intervention group).
[0055] Step 3, medication:
[0056] Combined treatment group: from the first day of radiotherapy, 4 tablets of Jinshuangqi tablets were given 3 times a day, and compound glutamine enteric-coated capsules were taken orally 3 capsules each time, 3 times a day, half an hour after meals, until 1 month after the end of radiotherapy;
[0057] Blank control group: no drug intervention;
[0058] Step 4, Evaluation:
[0059] Compared with the efficacy evaluation criteria, the tests were performed according to the test items to evaluate the incidence and remission rate of radiation proctitis, colonoscopy evaluation, imaging evaluation, changes in intestinal flora, inflammatory factor detection, and quality of life;
[0060] Step 5, statistical analysis:
[0061] The Kaplan-Meier method was used to calculate the incidence and remission rate of radiation proctitis in the subjects, and the Log-rank test was used to compare the differences between the two groups.
[0062] The details are as follows:
[0063] 1. Case selection:
[0064] The study subjects were 176 patients with locally advanced rectal cancer who were scheduled to undergo neoadjuvant concurrent chemoradiotherapy before surgery.
[0065] 1. Selection criteria
[0066] (1) Patients aged 18-75 years with locally advanced rectal adenocarcinoma confirmed by histopathology and clinical stage cT3-4N0-2M0 diagnosed by pelvic MRI who are scheduled to undergo neoadjuvant concurrent chemoradiotherapy before surgery;
[0067] (2) No concurrent other malignant tumors;
[0068] (3) Those without serious heart, liver, kidney or other diseases;
[0069] (4) Voluntarily sign the informed consent form;
[0070] (5) PS score: 0-1.
[0071] 2. Exclusion criteria
[0072] (1) Combined with ulcerative colitis or Crohn's disease;
[0073] (2) Combined with severe organ dysfunction, diabetes, and heart disease;
[0074] (3) Pregnant and lactating women;
[0075] (4) Intestinal motility abnormalities due to systemic or metabolic diseases;
[0076] (5) The patient has a history of using systemic antibiotics or intestinal active bacteria drugs in the past month.
[0077] 3. Termination criteria
[0078] The criteria for termination of the study are as follows:
[0079] (1) If the subject develops radiation proctitis ≥ grade 3 during or within one month after radiotherapy and after 2 weeks of combined treatment;
[0080] (2) The subject experiences bleeding, perforation, etc. during treatment and radiotherapy must be terminated;
[0081] (3) The subject experiences an adverse reaction that the subject cannot tolerate, and the investigator considers it necessary to stop the study treatment;
[0082] (4) The subject's compliance is poor and the investigator considers it necessary to stop the study treatment;
[0083] (5) Serious violation of the protocol, and the investigator considers it necessary to stop the study treatment;
[0084] (6) The subject voluntarily withdraws from the study treatment;
[0085] (7) Other reasons make the researcher believe that the subject is not suitable for continuing the research treatment.
[0086] 2. Test Items and Test Time
[0087] (1) Blood test: During neoadjuvant therapy, routine blood tests and biochemical 1+4 tests are required once a week to determine whether the patient can continue neoadjuvant chemoradiotherapy to ensure the safety of treatment. At the same time, blood samples are collected within 1 week before neoadjuvant therapy, during radiotherapy (about 14±2 fractions), at the end of radiotherapy, and 1 month after the end of radiotherapy for subsequent detection of inflammatory factors.
[0088] (2) Fiberoptic colonoscopy evaluation: Colonoscopy was used to observe the intestinal mucosal manifestations within 1 week before neoadjuvant therapy, during radiotherapy (approximately 14 ± 2 fractions), at the end of radiotherapy, and 1 month after the end of radiotherapy, using the Vienna colonoscopy scoring standard.
[0089] (3) Imaging evaluation: High-resolution + DWI pelvic enhanced MRI was performed within 1 month before neoadjuvant therapy and 1 month after the end of radiotherapy to evaluate tumor changes.
[0090] (4) Stool collection: Feces were collected from subjects one week before treatment, during radiotherapy (divided approximately 14 ± 2 times), and one month after treatment. Next-generation sequencing was used to detect changes in the intestinal flora of patients at different time points and to detect changes in the species and abundance of stool flora.
[0091] (5) Clinical symptoms and quality of life assessment: During neoadjuvant chemoradiotherapy, patients were followed up weekly to assess the frequency of bowel movements, duration of diarrhea, abdominal pain, abdominal distension, degree of tenesmus, presence of mucus and blood in the stool, and duration of remission using the RTOG acute radiation injury grading criteria. At the same time, the EORTC quality of life survey core questionnaire QLQ-C30 was used to assess the quality of life of patients weekly.
[0092] III. Efficacy evaluation criteria
[0093] (1) Effectiveness evaluation: During the neoadjuvant chemoradiotherapy, follow-up was performed weekly to evaluate the occurrence and grade of radiation proctitis in patients according to the RTOG acute radiation injury grading standard and record the results. Colonoscopy was used to observe the intestinal mucosal manifestations within 1 week before neoadjuvant treatment, during radiotherapy (about 14±2 divisions), at the end of radiotherapy, and 1 month after the end of radiotherapy, and the Vienna colonoscopy scoring standard was used. Within 1 month before neoadjuvant treatment and 1 month after the end of radiotherapy, high-resolution + DWI pelvic enhanced MRI was used to evaluate tumor changes according to RECIST1.1. In addition, the EORTC quality of life survey core questionnaire QLQ-C30 was used to evaluate the quality of life of patients every week.
[0094] (2) Safety evaluation: During neoadjuvant therapy, subjects need to be followed up in the outpatient clinic once a week for symptom questioning and physical examination, and blood routine and biochemical tests are performed weekly to determine whether the patient can continue neoadjuvant chemoradiotherapy to ensure the safety of treatment.
[0095] IV. Observation, Recording and Disposal of Adverse Events
[0096] Adverse events (AEs) refer to all adverse medical events that occur after subjects receive trial drugs. They can manifest as symptoms, signs, diseases, or abnormal laboratory tests, but they do not necessarily have a causal relationship with the trial drugs.
[0097] Serious adverse events: events that occur during clinical trials that require hospitalization, prolong hospitalization, cause disability, affect work ability, endanger life or death, or cause congenital malformations.
[0098] The trial drugs used in this study are all marketed drugs with good safety. The adverse events expected in this study are mainly those caused by neoadjuvant chemoradiotherapy, such as nausea, vomiting, abdominal pain, diarrhea, tenesmus and other symptoms.
[0099] All AEs must be recorded according to severity, severity (assessed according to CTCAE5.0), causal relationship with the trial drug, causal relationship with the trial process, measures taken for the trial drug, measures taken for AEs, and adverse event outcomes. All AEs that occur from the signing of the informed consent form to the last follow-up of the subject should be fully recorded and continuously followed up until the event is cured, returns to baseline, reaches a stable state, etc.
[0100] 5. Statistical Processing
[0101] Sample size estimation: A retrospective analysis of patients receiving neoadjuvant standard concurrent chemoradiotherapy showed that the incidence of grade ≥ 2 radiation proctitis was 30% (i.e., the incidence of radiation proctitis in the control group) without treatment intervention. It is estimated that with the intervention of the combined treatment group, the rate of grade ≥ 2 radiation proctitis will be reduced by 50%, i.e., the rate of grade ≥ 2 radiation proctitis in the combined treatment group will be 15%, α = 0.05, 1-β = 0.9, and the experimental group: control group were randomized in a 1:1 ratio. The final required sample size was calculated based on a 10% loss to follow-up rate, with 88 cases in each group, for a total of 176 subjects.
[0102] General principles: All statistical tests are two-sided tests, and the difference tested is considered statistically significant when the P value is less than or equal to 0.05. Measurement data are described statistically using mean, median, standard deviation, maximum, minimum, 25% and 75% quantiles; count data or rank data are described using frequency.
[0103] Efficacy analysis: The Kaplan-Meier method was used to calculate the incidence and remission rate of radiation proctitis in the subjects, and the Log-rank test was used to compare the differences between the two groups.
[0104] Safety evaluation method: Describe the number and percentage of adverse reactions in different treatment groups respectively.
[0105] Biomarkers: Descriptive statistics were used to analyze the changes in the expression and distribution of intestinal flora and inflammatory factors, and to explore the potential relationship between the above indicators and therapeutic efficacy.
[0106] The method provided by the present invention can observe and obtain the incidence of acute radiation proctitis of grade ≥2 in two groups of patients, as well as the remission rate of radiation proctitis after combined treatment for acute radiation proctitis of grade ≥2 in the control group, and can also conduct clinical symptom evaluation of radiation proctitis, fiberoptic proctoscopy evaluation, imaging evaluation, intestinal flora changes, inflammatory factor detection and quality of life evaluation on the combined treatment group.
[0107] The above shows and describes the basic principles, main features and advantages of the present invention. It is obvious to those skilled in the art that the present invention is not limited to the details of the above exemplary embodiments, and that the present invention can be implemented in other specific forms without departing from the spirit or basic features of the present invention. Therefore, no matter from which point of view, the embodiments should be regarded as exemplary and non-restrictive. The scope of the present invention is defined by the appended claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims are included in the present invention.
[0108] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. A method for evaluating the efficacy of Jinshuangqi combined with compound glutamine enteric-coated capsules. It is characterized in that The following steps are involved: Step 1, select patient samples: The sample criteria were set and cases were selected. The subjects were patients with locally advanced rectal cancer who were planned to undergo neoadjuvant synchronous chemoradiotherapy before surgery. Step 2, grouping: The selected patients were randomly divided into two groups, which were set as the combined treatment group and the blank control group; Step 3, medication: Combined treatment group: from the first day of radiotherapy, 4 tablets of Jinshuangqi tablets were given 3 times a day, and compound glutamine enteric-coated capsules were taken orally 3 capsules each time, 3 times a day, half an hour after meals, until 1 month after the end of radiotherapy; Blank control group: no drug intervention; Step 4, Evaluation: Compared with the efficacy evaluation criteria, the tests were performed according to the test items to evaluate the incidence and remission rate of radiation proctitis, colonoscopy evaluation, imaging evaluation, changes in intestinal flora, inflammatory factor detection, and quality of life; Step 5, statistical analysis: The Kaplan-Meier method was used to calculate the incidence and remission rate of radiation proctitis in the subjects, and the Log-rank test was used to compare the differences between the two groups.
2. A method for evaluating the efficacy of Jinshuangqi combined with compound glutamine enteric-coated capsules according to claim 1, It is characterized in that The standard of the sample in step 1 is: (1) Patients aged 18-75 years with locally advanced rectal adenocarcinoma confirmed by histopathology and clinical stage cT3-4N0-2M0 diagnosed by pelvic MRI who are scheduled to undergo neoadjuvant concurrent chemoradiotherapy before surgery; (2) No concurrent other malignant tumors; (3) Those without serious heart, liver, kidney or other diseases; (4) Voluntarily sign the informed consent form; (5) PS score: 0-1.
3. A method for evaluating the efficacy of Jinshuangqi combined with compound glutamine enteric-coated capsules according to claim 1, It is characterized in that The grouping ratio of the combined treatment group and the blank control group was 1:
1.
4. A method for evaluating the efficacy of Jinshuangqi combined with compound glutamine enteric-coated capsules according to claim 1, It is characterized in that In step 3, patients with grade ≥ 2 radiation proctitis in the control group were crossed over to the combined treatment group.
5. A method for evaluating the efficacy of Jinshuangqi combined with compound glutamine enteric-coated capsules according to claim 1, It is characterized in that The efficacy evaluation criteria are as follows: (1) Effectiveness evaluation: During neoadjuvant chemoradiotherapy, follow-up was performed weekly to evaluate the occurrence and grade of radiation proctitis in patients according to the RTOG acute radiation injury grading standard and record them; Colonoscopy was used to observe the intestinal mucosa within 1 week before neoadjuvant therapy, during radiotherapy, at the end of radiotherapy, and 1 month after radiotherapy, using the Vienna colonoscopy scoring criteria; Within 1 month before neoadjuvant therapy and 1 month after the end of radiotherapy, high-resolution + DWI pelvic enhanced MRI was used to evaluate tumor changes according to RECIST1.1; In addition, the EORTC quality of life survey core questionnaire QLQ-C30 was used to assess the patients’ quality of life every week; (2) Safety evaluation: During neoadjuvant therapy, subjects need to have outpatient follow-up once a week for symptom questioning and physical examination, and weekly blood routine and biochemical tests to determine whether the patient can continue with neoadjuvant chemoradiotherapy to ensure the safety of treatment.
6. A method for evaluating the efficacy of Jinshuangqi combined with compound glutamine enteric-coated capsules according to claim 1, It is characterized in that The test items include: (1) Blood test: During neoadjuvant therapy, routine blood tests and biochemical 1+4 tests are required once a week to determine whether the patient can continue neoadjuvant chemoradiotherapy to ensure the safety of treatment. At the same time, blood samples are collected within 1 week before neoadjuvant therapy, during radiotherapy, at the end of radiotherapy, and 1 month after the end of radiotherapy for subsequent detection of inflammatory factors. (2) Fiberoptic colonoscopy evaluation: Colonoscopy was used to observe the intestinal mucosa within 1 week before neoadjuvant therapy, during radiotherapy, at the end of radiotherapy, and 1 month after radiotherapy, using the Vienna colonoscopy scoring system. (3) Radiological evaluation: High-resolution + DWI pelvic enhanced MRI was used to evaluate tumor changes within 1 month before neoadjuvant therapy and 1 month after radiotherapy. (4) Stool collection: Feces of the subjects were collected one week before treatment, during radiotherapy, and one month after treatment. Next-generation sequencing was used to detect changes in the intestinal flora of the patients at different time points, and to detect changes in the species and abundance of stool flora. (5) Clinical symptoms and quality of life assessment: During neoadjuvant chemoradiotherapy, patients were followed up weekly to assess the frequency of bowel movements, duration of diarrhea, abdominal pain, abdominal distension, degree of tenesmus, presence of mucus and blood in the stool, and duration of remission using the RTOG acute radiation injury grading standard. At the same time, the EORTC quality of life survey core questionnaire QLQ-C30 was used to assess the quality of life of patients weekly.
Citation Information
Patent Citations
Method for evaluating curative effect of compound glutamine formula on diarrhea-predominant irritable bowel syndromes
CN111905111A
